CNS Pharmaceuticals Inc
CNSP6.580USD
-0.100-1.50%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.78M总市值
0.02市盈率 TTM
关于 CNS Pharmaceuticals Inc 公司
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc简介
公司代码CNSP
公司名称CNS Pharmaceuticals Inc
上市日期Nov 08, 2019
CEOClimaco (John Michael)
员工数量4
证券类型Ordinary Share
年结日Nov 08
公司地址2100 West Loop S Ste 900
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77027-3522
电话18009469185
网址https://cnspharma.com/
公司代码CNSP
上市日期Nov 08, 2019
CEOClimaco (John Michael)
CNS Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-37.50%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+100.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Mahery
Ms. Amy Mahery
Independent Director
Independent Director
--
-100.00%
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Lead Independent Director
Lead Independent Director
--
-100.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-37.50%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+100.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
UBS Financial Services, Inc.
1.63%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
其他
90.69%
持股股东
持股股东
占比
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
UBS Financial Services, Inc.
1.63%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
其他
90.69%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
5.19%
Investment Advisor
3.90%
Corporation
0.15%
Bank and Trust
0.07%
其他
90.69%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
34
57.74K
7.40%
+32.22K
2025Q3
34
25.52K
7.99%
-17.21K
2025Q2
30
42.73K
1.82%
+37.38K
2025Q1
30
5.15K
1.78%
+786.00
2024Q4
28
5.89K
1.26%
+3.16K
2024Q3
24
2.73K
0.48%
+2.49K
2024Q2
21
240.00
1.54%
+206.00
2024Q1
23
34.00
3.95%
+20.00
2023Q4
20
11.00
4.00%
+6.00
2023Q3
22
5.00
7.14%
--
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
UBS Financial Services, Inc.
2.67K
0.47%
+677.00
+33.88%
Jun 30, 2025
Cortice Biosciences, Inc.
956.00
0.17%
+956.00
--
Jul 30, 2024
Barrett & Company, Inc.
8.00
0%
--
--
Jun 30, 2025
Climaco (John Michael)
8.00
0%
--
--
May 09, 2025
BofA Global Research (US)
4.00
0%
+3.00
+300.00%
Jun 30, 2025
Downs (Christopher)
3.00
0%
--
--
May 09, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
公告日期
类型
比率
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Nov 28, 2022
Merger
30→1
查看更多
常见问题
CNS Pharmaceuticals Inc的前五大股东是谁？
CNS Pharmaceuticals Inc 的前五大股东如下：
UBS Financial Services, Inc.持有股份：2.67K，占总股份比例：0.47%。
Cortice Biosciences, Inc.持有股份：956.00，占总股份比例：0.17%。
Barrett & Company, Inc.持有股份：8.00，占总股份比例：0.00%。
Climaco (John Michael)持有股份：8.00，占总股份比例：0.00%。
BofA Global Research (US)持有股份：4.00，占总股份比例：0.00%。
UBS Financial Services, Inc.持有股份：2.67K，占总股份比例：0.47%。
Cortice Biosciences, Inc.持有股份：956.00，占总股份比例：0.17%。
Barrett & Company, Inc.持有股份：8.00，占总股份比例：0.00%。
Climaco (John Michael)持有股份：8.00，占总股份比例：0.00%。
BofA Global Research (US)持有股份：4.00，占总股份比例：0.00%。
CNS Pharmaceuticals Inc的前三大股东类型是什么？
CNS Pharmaceuticals Inc 的前三大股东类型分别是：
Stonepine Capital Management, LLC
DRW Securities, LLC
UBS Financial Services, Inc.
Stonepine Capital Management, LLC
DRW Securities, LLC
UBS Financial Services, Inc.
有多少机构持有CNS Pharmaceuticals Inc(CNSP)的股份？
截至2025Q4，共有34家机构持有CNS Pharmaceuticals Inc的股份，合计持有的股份价值约为57.74K，占公司总股份的7.40%。与2025Q3相比，机构持股有所增加，增幅为-0.59%。
哪个业务部门对CNS Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对CNS Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
